Cancer therapy has advanced with molecularly targeted approaches and immunotherapy, yet chemotherapy remains essential for ...

which aligns with the circumstances observed in non-small cell lung cancer. In view of these findings, we believe that PSRC1 may be a potential therapeutic target for SCLC.” “Moreover ...

The leading Extensive-Stage Small Cell Lung Cancer Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, ...

Bayer continues to form new partnerships to expand its targets for cancer treatment, recently collaborating with MOMA and ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment ... for the treatment of patients with Small Cell Lung Cancer (SCLC).

This precision enhances the effectiveness of cancer therapy and minimizes collateral damage. The typical components in a radiopharmaceutical critical for its ability to successfully reach its target ...

6, 2025 /PRNewswire/ -- Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical ... of patients with Small Cell Lung Cancer (SCLC). SCLC is a deadly condition ...

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to take a look at where Tango Therapeutics Inc. (NASDAQ:TNGX) stands against ...

225 Ac-satoreotide is a first-in-class Actinium-labelled somatostatin receptor 2 antagonist targeting extensive-stage Small Cell Lung Cancer or Merkel Cell Carcinoma Orphan Drug Designation ...